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SCIENTIFIC OPINION 
Scientific Opinion on Xylanase from a Genetically Modified Strain of 
Aspergillus oryzae (strain NZYM-FB)1, 2 
EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids 
(CEF)3, 4 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
The food enzyme considered in this opinion is a xylanase (endo-1,4-β-xylanase; EC 3.2.1.8) produced with a 
genetically modified strain of Aspergillus oryzae. The genetic modifications do not raise safety concern. The 
food enzyme contains neither the production organism nor recombinant DNA. The xylanase is intended to be 
used in a number of food manufacturing processes, such as starch processing, beverage alcohol (distilling), 
brewing, baking and other cereal based processes. The dietary exposure was assessed according to the Budget 
method. The food enzyme did not induce gene mutations in bacteria nor chromosome aberrations in human 
peripheral blood lymphocytes. Therefore, there is no concern with respect to genotoxicity. The systemic toxicity 
was assessed by means of a 90-day subchronic oral toxicity study in rodents.  A No Observed Adverse Effect 
Level was derived, which compared with the dietary exposure results in a sufficiently high Margin of Exposure. 
The allergenicity was evaluated by searching for similarity of the amino acid sequence to those of known 
allergens. The Panel considered that the likelihood of food allergic reactions to the enzyme is low and therefore 
does not raise safety concern. Based on the genetic modifications performed, the manufacturing process, the 
compositional and biochemical data provided and the toxicological studies, this food enzyme does not raise 
safety concern under the intended conditions of use. 
© European Food Safety Authority, 2014 
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opinion. 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Food Contact Material, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on 
the food enzyme xylanase (endo-1,4-β-xylanase; EC 3.2.1.8) produced with the genetically modified 
Aspergillus oryzae strain NZYM-FB.   
The A. oryzae parental strain has a long history of use for the production of food enzymes. It has been 
modified in order to produce and secrete xylanase and to prevent or decrease the production of 
undesirable secondary metabolites. The genetic modifications do not raise safety concern.  
The food enzyme contains neither the production organism nor recombinant DNA, given the limits of 
detection.  
The food enzyme has been characterised by determining the temperature and pH optima and the 
thermo-stability. Its composition is verified by measuring the content of protein, ash, water, heavy 
metals and Total Organic Solids. The A. oryzae parental strain has been modified in order to prevent 
the production of cyclopiazonic acid and to decrease the potential production of kojic acid. The 
absence of cyclopiazonic acid, β-nitropropionic acid and kojic acid was demonstrated, given the limits 
of detection.  
The food enzyme is intended to be used in a number of food manufacturing processes, such as starch 
processing, beverage alcohol (distilling), brewing, baking and other cereal based processes. The 
typical uses and the use levels recommended for specific food processes have been provided.  
The Theoretical Maximum Daily Intake was calculated according to the Budget method.  
The genotoxicity of the food enzyme was assessed by means of two in vitro assays (gene mutations in 
bacteria and chromosome aberrations in human lymphocytes). The food enzyme, produced with the 
genetically modified A. oryzae strain NZYM-FB, did not to induce gene mutations in bacteria with or 
without metabolic activation when tested under the conditions employed in the study as presented by 
the applicant. Neither did it induce chromosome aberrations in cultured human blood lymphocytes 
under the test conditions employed for this study. The systemic toxicity was assessed by means of a 
90-day subchronic oral toxicity study in rodents.  A No Observed Adverse Effect Level (NOAEL) was 
derived, which compared with the dietary exposure results in a sufficiently high Margin of Exposure.  
The CEF Panel considers that the likelihood of food allergic reactions to this xylanase produced with 
this genetically modified strain of A. oryzae is low and therefore does not raise safety concern. 
Based on the genetic modifications performed, the manufacturing process, the compositional and 
biochemical data provided and the toxicological studies, the Panel concluded that this food enzyme 
does not raise safety concern under the intended conditions of use. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION  
Only food enzymes included in the Union list may be placed on the market as such and used in foods, 
in accordance with the specifications and conditions of use provided for in Article 7 (2) of Regulation 
(EC) No 1332/20085 on food enzymes. According to Regulation (EC) No 1332/2008 on food 
enzymes, a food enzyme which falls within the scope of Regulation (EC) No 1829/20036 on 
genetically modified food and feed should be authorised in accordance with that Regulation as well as 
under this Regulation. 
An application has been introduced by the company Novozymes A/S for the authorisation of the food 
enzyme xylanase from a genetically modified strain of Aspergillus oryzae (strain NZYM-FB). 
Following the requirements of Article 12.1 of Commission Regulation (EU) No 234/20117 
implementing Regulation (EC) No 1331/20088, the Commission has verified that the application falls 
within the scope of the food enzyme Regulation and contain all the elements required under Chapter II 
of that Regulation. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
The European Commission requests the European Food Safety Authority to carry out the safety 
assessment on the food enzyme xylanase from a genetically modified strain of Aspergillus oryzae 
(strain NZYM-FB) in accordance with Article 17.3 of Regulation (EC) No 1332/2008 on food 
enzymes. 
 
 
                                                     
5  Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and 
Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/199, Directive 2000/13/EC, Council 
Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7-15. 
6  Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically 
modified food and feed. OJ L 268, 18.10.2003 p. 1-23. 
7 Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the 
European Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes 
and food flavourings. OJ L 64, 11.03.2011, p. 15-24. 
8 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a 
common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p. 1-6. 
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ASSESSMENT 
1. Introduction 
Before January 2009 food enzymes other than those used as food additives were not regulated or were 
regulated as processing aids under the legislation of the Member States. On 20 January 2009 the 
Regulation (EC) No 1332/2008 on food enzymes entered into force. This Regulation applies to 
enzymes that are added to food to perform a technological function in the manufacture, processing, 
preparation, treatment, packaging, transport or storage of such food, including enzymes used as 
processing aids. The Regulation (EC) No 1331/2008 established Union procedures for the safety 
assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The 
use of a food enzyme shall only be authorised if it is demonstrated that:  
(i) it does not pose a safety concern to the health of the consumer at the level of use 
proposed;  
(ii) there is a reasonable technological need, and  
(iii) its use does not mislead the consumer.  
All food enzymes currently on the EU market and intended to remain on that market as well as all new 
food enzymes shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) 
and an approval via a Union list. 
The Guidance on submission of a dossier on a food enzyme for evaluation by EFSA (EFSA, 2009) 
lays down the administrative, technical and toxicological data required. 
In the case of enzymes produced with genetically modified microorganisms (GMM) the guidance on 
the risk assessment of GMM and their products intended for food and feed use (EFSA GMO Panel, 
2011) applies.  
The assessment of a GMM aims to evaluate the safety of the food enzyme related to the genetic 
modifications. This starts from the evaluation of the safety of the parental/recipient and donor strains, 
e.g. regarding their capability to produce undesirable metabolites. It also includes the assessment of 
the genetic modifications, specifically of the introduction of genes of concern and the genetic stability. 
Finally, the presence of the production organism and its recombinant DNA in the final product is 
assessed. Special attention is paid to the presence of any recombinant genes of concern (e.g. antibiotic 
resistance genes), introduced during the development of the production strain. If the absence of the 
production strain and the recombinant DNA has been confirmed, no extensive environmental risk 
assessment of the enzyme product is required. 
The following evaluation applies to the xylanase (endo-1,4-β-xylanase; EC 3.2.1.8) produced with the 
genetically modified A. oryzae strain NZYM-FB. 
2. Information on existing authorisations and evaluations 
The applicant reports that the Danish, French and South Korean authorities have evaluated and 
authorised the use of the xylanase food enzyme produced with the genetically modified A. oryzae 
strain NZYM-FB in a number of food manufacturing processes, such as starch processing, alcohol 
distilling, brewing and baking processes. Only the Danish authority specified the conditions of use, i.e. 
max. 200 FXU(S)9/kg wheat flour for starch and gluten products and max. 100 FXU(S)/kg for barley 
or malt.  
 
                                                     
9 Fungal Xylanase Units 
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3. Technical data 
3.1. Identity of the food enzyme 
IUBMB nomenclature:  Endo-1,4-β-xylanase  
Systematic name:  1,4-β-D-Xylan xylanohydrolase 
Synonyms: Xylanase; endo-1,4-D-β-xylanase 
IUBMB No:  EC 3.2.1.8  
CAS No:  9025-57-4  
EINECS No:  232-800-2. 
3.2. Chemical parameters 
The xylanase produced with the genetically modified A. oryzae strain NZYM-FB is a single 
polypeptide chain of 384 amino acids. The molecular mass derived from the amino acid sequence was 
calculated to be 40.8 kDa.  
Data on the chemical parameters and the protein homogeneity status of the food enzyme have been 
provided for three enzyme preparation batches and for the food enzyme batch (PPJ 6867) used for the 
toxicological tests (Table 1).   
The average Total Organic Solids (TOS) of the three enzyme preparation batches was 10.6 % (w/w); 
the values ranged from 9.3 to 11.6 % (Table 1). TOS is a calculated value derived from 100 % minus 
% water % minus % ash and minus % diluents (stabilisation and formulation ingredients). The three 
enzyme preparation batches presented in Table 1 are ultra-filtered concentrates, which were stabilised 
and preserved by addition of potassium sorbate, sodium benzoate, sorbitol and glycerol. The batch 
used for toxicological tests does not contain any diluents. 
The average specific activity of the enzyme preparations expressed as ratio enzyme activity/mg TOS 
was 23.6 FXU(S)/mg TOS; the values ranged from 21.5 to 26.1 FXU(S)/mg TOS (Table 1). 
Considering the low variability of the activities as well as the specific activities in the three enzyme 
preparations, the average activity/mg TOS value of 23.6 FXU(S)/mg TOS was used for subsequent 
calculations.  
A. oryzae, as a species, is known to have the potential to produce undesirable secondary metabolites 
such as cyclopiazonic acid (CPA), β-nitropropionic acid (NPA) and kojic acid (KA) (Blumenthal, 
2004). Accordingly, these mycotoxins must be checked in the final food enzyme from A. oryzae 
(FAO/WHO, 2006). A. oryzae as a species belongs to the Aspergillus flavus group which is known to 
have a gene cascade for the biosynthesis of aflatoxins, but under any known fermentation conditions, 
A. oryzae strains never produced aflatoxins (Blumenthal, 2004; Lee et al., 1991). The parental strain 
has been modified by γ-irradiation mutagenesis, resulting in the deletion of gene clusters required for 
the synthesis of the mycotoxins cyclopiazonic acid (cpa) and aflatoxin (afl). UV irradiation 
mutagenesis resulted in a reduced potential (15 % of the original) to produce kojic acid. None of these 
three species-specific mycotoxins (CPA, NPA and KA) were detected in the food enzyme (Table 1) by 
mass spectrometry (LC-MS/MS).  
The protein homogeneity status of the food enzyme was also investigated by SDS-PAGE analysis. The 
apparent molecular mass based on this technique is about 45 kDa (compared to the calculated 
molecular mass of 40.8 kDa). According to the applicant, this is most likely due to glycosylation, a 
common feature of proteins of Aspergillus. The gels presented for the four batches were comparable; 
Xylanase from Aspergillus oryzae strain NZYM-FB
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variations in the relative amounts of the protein bands were suggested by the applicant to be caused by 
different glycosylation patterns.  
The food enzyme was tested for other enzyme activities, i.e. alpha-amylase, glucoamylase, protease 
and lipase activities, which were below the detection limits of the employed methods (Table 1). 
Table 1:  Compositional data of the food enzyme  
Parameter Unit Batches 
  CDG00157 CDG00158 CDG00159 PPJ 6867(a)
Xylanase activity FXU(S)/g batch(b) 2 500 2 490 2 430 2 000 
Protein % (w/w) 7.1 6.9 7.3 7.1 
Ash % (w/w) 0.3 < 0.3 0.3 2.3 
Water % (w/w) 61.7 61.6 61.8 87.6 
Total Organic Solids 
(TOS)(c) % (w/w) 10.8 11.6 9.3 10.1 
Activity/mg TOS FXU(S)/mg TOS 23.1 21.5 26.1 19.8 
Pb mg/kg batch ND(d) ND(d) ND(d) ND(d) 
As mg/kg batch ND(d) ND(d) ND(d) ND(d) 
Cd mg/kg batch ND(d) ND(d) ND(d) ND(d) 
Hg mg/kg batch ND(d) ND(d) ND(d) ND(d) 
Antimicrobial activity  ND(d) ND(d) ND(d) ND(d) 
Production strain CFU per g batch NA(e) NA(e) NA(e) ND(d) 
Cyclopiazonic acid mg/kg batch ND(d) ND(d)  ND(d)  ND(d) 
Kojic acid mg/kg batch ND(d) ND(d) ND(d) ND(d) 
β-nitropropionic acid mg/kg batch ND(d) ND(d) ND(d) ND(d) 
Antifoam agents mg/kg batch 352 1 307 781 1 410 
Alpha-amylase FAU(F)/g batch(f) ND(d) ND(d) ND(d) ND(d) 
Glucoamylase AGU/g batch(g) ND(d) ND(d) ND(d) ND(d) 
Protease HUT/g batch(h) ND(d) ND(d) ND(d) ND(d) 
Lipase KLU/g batch(i) ND(d) ND(d) ND(d) ND(d) 
(a): Batch used for the toxicological tests (Food enzyme before stabilisation and formulation (See footnote c)). 
(b): FXU(S): Fungal Xylanase Units (relative to an internal enzyme standard “S”) (see Section 3.3). 
(c): TOS calculated as 100 % - % water - % ash - % diluents (Diluents: potassium sorbate, sodium benzoate, sorbitol and 
glycerol used for stabilisation of the enzyme preparation batches CDG00157, CDG00158 and CDG00159 in accordance 
with Commission Regulation (EU) No 1130/201110). 
(d): ND: Not detected: below the limits of detection (Pb: 0.5 mg/kg, for the food enzyme batch PPJ 6867 the limit of 
detection was 1 mg/kg; As: 0.1 mg/kg; Cd: 0.05 mg/kg; Hg: 0.03 mg/kg; cyclopiazonic acid: 0.01 mg/kg; kojic acid: 0.2 
mg/kg, for the batch PPJ 6867 the limit of detection was 2 mg/kg; β-nitropropionic acid: 0.3 mg/kg; alpha-amylase: 0.34 
FAU(F)/g; glucoamylase: 0.825 AGU/g: protease: 196 HUT/g: lipase: 0.02 KLU/g; antimicrobial activity: inhibition 
zone diameters ≤ 16 mm imply that the antimicrobial activity was absent (FAO/WHO, 2006)). According to the 
applicant, the differences in the detection limits for lead and kojic acid in the three enzyme preparations and in the food 
enzyme batch used for toxicological testing are due to differences in the performances of the methods at the respective 
point in time of the analysis.  
(e): NA: Not analysed. 
(f): FAU(F): Fungal alpha-Amylase Units (relative to an internal enzyme standard “F”). 
(g): AGU: AmyloGlucosidase Units. 
(h): HUT: Hemoglobin Units Tyrosine. 
(i): KLU: Kilo Lipase Units.  
                                                     
10  Commission Regulation (EU) No 1130/2011 of 11 November 2011 amending Annex III to  
 Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives by  
 establishing a Union list of food additives approved for use in food additives, food enzymes, food  
 flavourings and nutrients. OJ L 295, 12.11.2011, p. 178-204. 
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The food enzyme complies with the microbiological criteria as laid down in the general specifications 
and considerations for enzymes used in food processing (FAO/WHO, 2006), which stipulate that 
Escherichia coli and Salmonella species are absent in 25 g of sample, and total coliforms are not more 
than 30 CFU (Colony Forming  Units) per gram.  
The applicant has provided information on the identity of the antifoam agents and the Panel considers 
the use of these as of no safety concern.  
The provided data regarding compositional batch-to-batch-variability are considered sufficient. Table 
1 shows that the food enzyme batch PPJ 6867 used for the toxicological assays has a lower activity/mg 
TOS and a higher level of inorganic constituents and antifoam agents. Consequently, this food enzyme 
batch PPJ 6867 is cruder than the three enzyme preparations and its use for the toxicological testing is 
considered suitable.  
3.3. Properties of the food enzyme 
Xylanases catalyse the hydrolysis of 1,4-β-D-xylosidic endo-linkages in xylan (including 
arabinoxylan, which is xylan branched with arabinose) resulting in the generation of (1→4)-β-D-xylan 
oligosaccharides of different lengths. The xylanase of A. oryzae strain NZYM-FB does not require co-
factors. 
The enzymatic activity is quantified based on the hydrolysis of wheat arabinoxylan and is expressed in 
Fungal Xylanase Units/g (FXU(S)/g). The xylanase activity is measured relative to an internal enzyme 
standard (“S”). The analytical principle is based on hydrolysis of the arabinoxylan to reducing 
carbohydrates (reaction conditions: pH = 6.0, T = 50 °C, incubation time = 5 minutes). The reaction is 
stopped by adding p-hydroxy benzoic acid hydrazide (PAHBAH) and bismuth (III)-tartrate which 
complexes with the reducing carbohydrates, producing a colour that is detected spectrophotometrically 
at 405 nm. 
The food enzyme has been characterised regarding its activity depending on temperature and pH. The 
xylanase is active at temperatures up to 80 °C (with an optimum of 60 - 70 °C at pH 6.0) and within a 
pH range of 3 to 8 (with an optimum of pH 3 - 4 at 37 °C). The thermo-stability of the food enzyme 
was tested over the range of 25 °C to 90 °C after a pre-incubation at the different temperatures at pH 
6.0 for 30 minutes. The activity itself was measured under standard conditions. The food enzyme 
shows 50 % residual activity at 60 - 65 °C after 30 minutes incubation and above 80 °C, no enzyme 
activity remains after 30 minutes. 
3.4. Information on the source materials 
3.4.1. Information relating to the genetically modified microorganism 
3.4.1.1. Characteristics of the recipient and parental microorganisms  
The production organism is the fungus A. oryzae. A. oryzae strains are not qualified as QPS (Qualified 
Presumption of Safety) because of the potential of mycotoxin production (EFSA BIOHAZ, 2012). The 
parental strain, A. oryzae A1560, has a long history of use for the production of food enzymes. The 
recipient strain A. oryzae BECh2, has been developed from the parental strain, A. oryzae A1560, 
through a series of modification steps including classical mutagenesis and genetic modification (the 
latter not described for confidentiality reasons).  
The classical mutagenesis steps included γ-irradiation mutagenesis, resulting in the deletion of gene 
clusters required for the synthesis of the mycotoxins cyclopiazonic acid (cpa) and aflatoxin (afl), and 
UV irradiation mutagenesis, resulting in a drastically reduced potential (15 % of the original) to 
produce kojic acid. A Southern blot analysis confirmed the absence of antibiotic resistance genes 
which were used during the genetic modification of the recipient strain. 
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3.4.1.2. Characteristics of the donor organisms  
The plasmid vector used for the transformation of the recipient strain contained elements to control the 
expression of the gene of interest as well as ensure integration of the introduced DNA into the 
recipient strain chromosome. The DNA introduced into the recipient strain did not contain antibiotic 
resistance genes.  
3.4.1.3. Description of the genetic modification process  
The production strain A. oryzae NZYM-FB was developed from the recipient strain BECh2 through 
transformation with a plasmid vector and selection of the transformants on appropriate medium. 
The production strain differs from the recipient strain by the synthesis and secretion of endo-1,4-β-
xylanase. 
3.4.1.4. Safety aspects of the genetic modification: Information relating to the GMM and comparison 
of the GMM with its conventional counterpart  
In comparison to the parental strain A1560, the recipient strain has lost the potential to produce 
cyclopiazonic acid and has a reduced potential to produce kojic acid. 
The final production strain NZYM-FB differs from the recipient strain by the synthesis and secretion 
of endo-1,4-β-xylanase.  
The presence of the gene encoding endo-1,4-β-xylanase in the NZYM-FB strain was verified by 
Southern analysis; this indicated that multiple copies of the full-length gene were integrated in the 
chromosomal DNA of the recipient. In order to estimate the number of copies, a dot blot analysis was 
carried out.  
Southern analysis of the DNA production strain from three independent enzyme preparation batches at 
the end of pilot scale fermentation confirmed the genetic stability of the genetic modifications. 
The genetic modifications do not raise safety concern. 
3.4.1.5. Safety for the environment 
Neither the production strain nor its recombinant DNA were detected in the final product (see Section 
3.5.2). Accordingly, as the food enzyme belongs to Category 2 of the guidance on risk assessment of 
genetically modified microorganisms and their products (EFSA GMO Panel, 2011), environmental 
exposure to the genetically modified microorganism or its DNA is negligible and hence no further 
environmental risk assessment is required. 
3.5. Manufacturing process 
The manufacturing process includes a fermentation process and downstream processing. A 
comprehensive dataset related to the manufacturing process including a flow diagram was provided. 
The food enzyme is manufactured according to the Regulation (EC) No 852/200411. According to the 
applicant the manufacturing process is certified according to Food Safety Systems Certification 22000 
(FSSC 22000) and ISO 9001. 
3.5.1. Information relating to the fermentation process 
The food enzyme is produced by a pure culture in contained submerged fed-batch fermentation with 
conventional process controls in place. The identity and the purity of the culture are checked at each 
transfer step from frozen vials to the end of fermentation.  
                                                     
11  Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food  
  additives. OJ L 226, 25.6.2004, p. 3-21. 
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3.5.2. Information relating to the downstream processing 
The downstream processing includes recovery, purification and concentration. The food enzyme 
produced is recovered from the fermentation broth after biomass separation via filtration. Further 
purification and concentration involve a series of filtration steps, including ultrafiltration and final 
germ filtration.  
The production strain could not be detected in a test volume of 1 g of three independent liquid batches 
tested in triplicate by liquid culturing in non-selective medium for 4 days (for resuscitation) followed 
by growth on selective solid agar plates for 4 days at a suitable temperature favouring the growth of 
the production strain. No recombinant DNA was detected starting with 1 g of three samples of the 
concentrated product before formulation obtained from three independent production batches and 
tested in triplicate. Analysis was performed by PCR, amplifying a 1 076 bp recombinant fragment 
spanning the deletion of an endogenous gene specific for the strain lineage, introduced in the first 
genetic modification step of the parental strain. 
3.6. Reaction and fate in food 
The xylanase catalyses the hydrolysis of 1,4-β-D-xylosidic endo-linkages in xylan (including 
arabinoxylan, which is xylan branched with arabinose) resulting in the production of (1→4)-β-D-xylan 
oligosaccharides of different lengths and xylose. 
Xylanase is specific in its action, not known to catalyse other reactions than this endo-hydrolysis of 
xylans to shorter xylans chains, xylo-oligosaccharides and xylose. These reaction products are 
naturally present in xylan-containing foods. The data and information provided indicate that the 
xylanase is denatured and/or removed during processing under the intended use conditions. The food 
enzyme was tested for other enzyme activities, i.e. alpha-amylase, glucoamylase, protease and lipase 
activities, which were below the detection limits of the employed methods. Therefore, no unintended 
products resulting from the xylanase and any side activities are to be expected. 
3.7. Case of need and intended conditions of use 
The food enzyme is intended to be used in a number of food manufacturing processes. Typical uses 
provided by the applicant are listed in Table 2.  
Table 2:  Typical uses and recommended maximum use levels of the food enzyme as provided by 
the applicant  
Process Recommended dosage of the food enzyme 
Starch processing Up to 600 FXU(S)/kg of wheat flour or cereal dry 
matter 
Beverage alcohol (distilling) processes Up to 600 FXU(S)/kg of wheat flour or cereal dry 
matter 
Brewing processes and other cereal-based beverage 
processes 
Up to 400 FXU(S)/kg of grits (e.g. barley, malt, 
wheat, rice), corresponding to 16.9 mg TOS/kg (400 
FXU(S)/23.6 FXU(S)/mg TOS (23.6 is the average 
of the three enzyme preparation batches)) 
Baking processes and other cereal-based processes Up to 650 FXU(S)/kg of wheat flour or cereal dry 
matter corresponding to 27.5 mg TOS/kg (650 
FXU(S)/23.6 FXU(S)/mg TOS (23.6 is the average 
of the three enzyme preparation batches)) 
 
Wheat, barley and other cereals are highly complex raw materials causing technical difficulties during 
processing. 
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In starch processing, the xylanase is added to the water before mixing the raw materials in both the 
wheat dough process and the wheat decanter process. It is used in order to improve the processes for 
the separation of starch, gluten and fibres, mainly by removing the arabinoxylans and reducing the 
viscosity of the water soluble arabinoxylans, resulting in energy savings due to less use of process 
water and lower evaporation costs. 
In the beverage alcohol (distilling) process, the xylanase is intended to be used in order to improve the 
manufacturing steps by reducing the viscosity, thereby improving heat exchange and centrifugal 
separation and to increase the yield of fermentable sugars from xylan hydrolysis. The xylanase is 
mainly added during the slurry mixing. In addition, the xylanase can also be added at the liquefaction 
or the fermentation steps. 
In the brewing process and other cereal based beverage processes, the xylanase is mainly used in order 
to easy filtrations and increase the flexibility in the choice of raw materials. The xylanase is added 
during the mashing step or alternatively during the cooking/liquefaction step and to get more uniform 
and predictable processes.  
In baking and other cereal based processes, the xylanase is added to raw materials during the 
preparation of the dough. It is used to hydrolyse arabinoxylans which react with gluten and water and 
thus contribute to the viscosity of the dough. Its use gives improved crumb structure and facilitates the 
handling of the dough, resulting in more uniform products. In other cereal based processes, the benefit 
of the use of xylanase is also a faster drying step.  
According to the applicant, the food enzyme is used at the minimum dosage necessary to achieve the 
desired reaction according to Good Manufacturing Practice (GMP). The dosage applied in practice by 
a food manufacturer depends on the particular process (see Table 2). 
4. Dietary exposure 
The exposure assessment was performed according to the Budget method (FAO/WHO, 2009). This 
method has been used as a screening method in assessing food additives by the JECFA (FAO/WHO, 
2001) and for assessments within the EU Scientific Cooperation (SCOOP) Task 4.2 (EC, 1998). The 
approach is based on the maximising assumptions that 25 % of consumed solid foods and 25 % of 
consumed beverages would be manufactured using the food enzyme and that all of the food enzyme 
would remain in the final processed food products. It is expected that the enzyme would be inactivated 
and/or residues of the food enzyme would be removed in the course of the production and processing 
of final food products. However, considering that the xylan hydrolysates resulting from the use of the 
food enzyme may be used in a variety of applications as ingredients of food and/or beverages, the 
Panel considered it appropriate to use this conservative upper-bound screening approach as part of a 
tiered approach to estimate the dietary exposure.  
The Panel followed the principles of the stepwise approach, which was used to assess Theoretical 
Maximum Daily Intake (TMDI).  
The estimation is based on the following assumptions:  
• The level of consumption of foods and of non-milk beverages: 
The levels of consumption of foods and beverages considered are maximum physiological 
levels that can be consumed each day - i.e. the daily consumption of 0.1 L/kg body weight 
(bw) of non-milk beverages and the daily consumption of 100 kcal/kg bw from foods 
(equivalent to 0.05 kg/kg bw based on an estimated energy density of 2 kcal/g). These levels 
correspond to the daily consumption of 6 L of non-milk beverages and 3 kg of food by a 
person with a body weight of 60 kg (typical adult) and a daily consumption of 1.5 L of non-
milk beverages and 750 g of food by a person with a body weight of 15 kg (typical three year-
old child) (FAO/WHO, 2009). 
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• The level of presence of the food enzyme in foods and in non-milk beverages: 
The level present in foods and non-milk beverages is assumed to be the highest recommended 
maximum use level of the food enzyme, expressed in mg of TOS per kg of product (or 
substrate, or ingredient), reported in any representative category by the applicant, respectively, 
for foods and beverages. The highest recommended maximum use level is 27.5 mg TOS per 
kg wheat flour or cereal dry matter for baking and other cereal-based processes and 16.9 mg 
TOS per kg grits (e.g. barley, malt, wheat, rice) for brewing processes (Table 2).   
• The proportion of foods and of non-milk beverages that may contain the food enzyme:  
The proportion of solid foods and beverages that may contain the food enzyme is set generally 
at 25 %. The default proportion (25 %) of beverages and solid food that could contain the 
enzyme was considered adequate. Although xylanase may be used in a variety of solid foods 
and beverages that could represent more than 25 % of processed foods, it is unlikely that a 
person would systematically choose all processed foods with the same enzyme added even 
considering brand loyalty. This assumes that a typical adult weighing 60 kg consumes daily 
1.5 L of beverage and 750 g of solid foods containing the food enzyme.  
In case the food enzyme is proposed for products particularly designed for infants or young children, 
ad hoc conservative exposure estimates must be made taking specifically into account these 
population groups. Otherwise, the very conservative approach described above, is considered to cover 
both adults and children. 
Assuming the conservative scenario described above and also that all processed foods and beverages 
would contain respectively 70 %12 and 17 %13 of cereal or grain ingredients, the Panel estimated that 
the theoretical maximum daily intake of the xylanase food enzyme from this genetically modified A. 
oryzae strain would be approximately 0.31 mg TOS/kg bw (27.5 mg TOS/kg x 0.05 kg/kg bw x 25 % 
x 70 %) + (16.9 mg TOS/kg x 0.1 L/kg14 bw x 25 % x 17 %). 
5. Toxicological data 
The toxicological assays were performed with a food enzyme (batch PPJ 6867, see Table 1) 
representative of the food enzyme before stabilisation and formulation, i.e. before addition of other 
components such as glycerol and sorbitol. 
Genotoxicity testing 
In order to investigate the potential to induce gene mutations in bacteria, an Ames test was performed 
according to OECD Test Guideline 471 (OECD, 1997a) and following Good Laboratory Practice 
(GLP) in four strains of Salmonella typhimurium (TA1535, TA100, TA1537, TA98) and Escherichia 
coli WP2uvrA, in the presence or absence of metabolic activation by S9 mix applying the “plate 
incorporation assay”. Two experiments were carried out using six different concentrations of the food 
enzyme using appropriate positive control chemicals and phosphate buffer as a negative control. The 
highest concentration was 5 000 µg dry matter/plate, corresponding to ca. 4 100 µg TOS/plate.  
According to the applicant, all positive control chemicals induced significant increases in revertant 
colony numbers, confirming the sensitivity of the tests and the efficacy of the S9 mix, while the 
negative controls were within the normal ranges. Upon treatment with the food enzyme there was no 
increase in revertant colony numbers, except for one strain of Salmonella typhimurium at the highest 
concentration of the food enzyme tested. The increased number of revertants was not concentration-
related, but was assumed by the applicant to be due to histidine present in the food enzyme. For that 
reason, the experiment was repeated applying a “treat and plate assay”, in which the Salmonella 
typhimurium strain was exposed to six concentrations of the food enzyme in a liquid medium for 3 
hours before plating the centrifuged cells. No increase of revertant colony numbers was observed. 
                                                     
12 100 g flour gives 140 g bread.  
13  In general, 1 kg of grain gives 6 kg of beer. 
14  It is assumed that the densities of beverages are ~1. 
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Therefore, it was concluded that the food enzyme has no mutagenic activity, under the conditions 
employed.  
 
The in vitro chromosome aberration test carried out according to the OECD Test Guideline 473 
(OECD, 1997b) and following GLP. Cultured human peripheral blood lymphocytes, the division of 
which was stimulated with phytohaemagglutinin (PHA), were treated with purified water (negative 
control), the food enzyme or appropriate positive controls (4-nitroquinoline 1-oxide or 
cyclophosphamide in the absence or the presence of the S9 mix, respectively). Two experiments were 
performed. In the first experiment, applying 3 + 17 hours treatment, the cultures were exposed to the 
food enzyme (3 200, 4 000 and 5 000 µg food enzyme/ml corresponding to ca. 320, 400 and 500 μg 
TOS/ml) for 3 hours, either in the presence or the absence of the S9 mix. In the second experiment, the 
concentrations of the food enzyme tested were 2 813, 3 750 and 5 000 μg food enzyme/ml 
(corresponding to ca. 280, 380 and 500 μg TOS/ml); a 20 + 0 hours treatment, where cultures were 
exposed to the food enzyme for 20 hours without the S9 mix and a 3 + 17 hours treatment with the S9 
mix, were applied. In all cases, the cells were harvested 20 hours after the beginning of treatment. 
Only cells with 44 to 46 chromosomes were considered. For all food enzyme concentrations used, the 
frequency of cells with chromosomal aberrations was similar to that of negative controls (values of 
p ≤ 0.05 were considered as significant). It was concluded that the food enzyme did not induce 
chromosomal aberration in cultured human peripheral blood lymphocytes when tested up to 5 000 μg 
food enzyme/ml (corresponding to ca. 500 μg TOS/ml) under the experimental conditions employed.  
Repeated dose toxicity testing 
A 90-day subchronic oral toxicity study was performed according to OECD Test Guideline 408 and 
following GLP (OECD, 1998). Four groups of 10 male and 10 female SPF Sprague Dawley rats were 
given by gavage a dose of 10 ml/kg bw/day tap water, a 10 % solution, a 33 % solution as well as an 
undiluted stock solution of the food enzyme for 13 weeks. The doses were equivalent to 0, 2100, 7700 
and 21100 FXU(S)/kg bw/day or 0, 106, 390 and 1 070 mg TOS/kg bw/day. 
Blood analysis revealed changes already from the mid dose female’s group; statistically significant 
decrease in red blood cells (RBC) and white blood cells (WBC), as well as a considerable decrease on 
neutrophils (NEUTRO). A statistically significant increase on the Mean Cell Volume (MCV) in the 
high dose female’s group and a statistically significant decrease on the lymphocytes count in the low 
and high dose female’s group were also observed.  
A small increase in the incidence and severity of extramedullary haemopoiesis (EMH) in the spleen 
was reported in female rats receiving the mid and high dose. A small increase in absolute and relative 
spleen weight (12 % and 10 %, respectively) which becomes statistically significant in the high dose 
female’s group (23 % and 21 %, respectively) was also reported.   
Though the magnitude of some of these effects was small in the mid dose level, the Panel decided that, 
as they could be considered as likely indicative of the same effects (i.e. decrease in the RBC and 
effects in spleen) and the system disturbance could increase susceptibility, these changes should be 
considered adverse. Consequently, the Panel derived a NOAEL on the low dose level of 106 mg 
TOS/kg bw/day. 
6. Allergenicity 
Potential allergenicity of xylanase was assessed by comparing its amino acid sequence with those of 
known allergens according to the scientific opinion on the assessment of allergenicity of GM plants 
and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified 
Organisms (EFSA GMO Panel, 2010). Using higher than 35 % identity in a window of 80 amino acids 
as the criterion, no match was found. No food allergic reactions to xylanase have been reported in the 
literature. 
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Consequently, the CEF Panel considers that the likelihood of food allergic reactions to this xylanase 
produced with the genetically modified strain of A. oryzae is low and therefore does not raise safety 
concern. 
7. Discussion 
The parental strain A. oryzae A1560 has a long history of use for the production of food enzymes. The 
recipient strain, A. oryzae BECh2, was developed from the parental strain through a series of 
modification steps including classical mutagenesis and genetic modification. The A. oryzae production 
strain NZYM-FB contains a recombinant gene encoding xylanase. Multiple copies were randomly 
integrated into the genomic DNA as part of the plasmid vector. The introduced trait is well-known and 
does not trigger a safety concern. No sequences that can cause safety concern (e.g. antibiotic resistance 
genes) remained. Neither the production strain nor the recombinant DNA are detected in the final 
products by methods considered adequate by the CEF Panel.  
The information provided on the manufacturing of the food enzyme, i.e. the fermentation conditions 
and the steps employed for isolation and purification, is considered sufficient. The available 
compositional data, including experimental evidence of the absence of potential contaminants such as 
mycotoxins, sufficiently demonstrate the identity and the purity of the food enzyme. The reported 
batch-to-batch variability is considered acceptable. 
The process conditions provided indicate that the enzyme is inactivated and/or removed in the course 
of the intended food applications.  
Taking the proposed uses and the recommended maximum use levels into account, a dietary exposure 
assessment based on the Budget Method resulted in a TMDI of 0.31 mg TOS/kg bw. The Panel is 
aware that the exposure assessment performed is highly conservative because it does not take into 
account factors such as inactivation and removal of the enzyme during food processing. 
The food enzyme produced with the genetically modified A. oryzae strain NZYM-FB did not induce 
gene mutations in bacteria with or without metabolic activation. Neither did it induce chromosome 
aberrations in cultured human blood lymphocytes. 
A comparison of the NOAEL (106 mg TOS/kg bw/day) from the 90-day study with the TMDI 
(assessment performed according to the Budget method; Section 4), calculated to be 0.31 mg TOS/kg 
bw/day, results in a margin of exposure (MOE) of 345, which is found sufficient in the light of the 
conservative interpretation of the effects observed in the 90-day oral toxicity study and the 
conservative nature of the exposure estimate.  
The CEF Panel considers that the likelihood of food allergic reactions to the xylanase from this 
genetically modified strain of A. oryzae is low and therefore does not raise safety concern. 
CONCLUSIONS  
Based on the genetic modifications performed, the manufacturing process, the compositional and 
biochemical data provided and findings in the toxicological studies, the food enzyme “Xylanase from 
a genetically modified strain of Aspergillus oryzae (strain NZYM-FB)” does not raise safety concern 
under the intended conditions of use. 
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ABBREVIATIONS 
Afl   Aflatoxin 
AGU   AmyloGlucosidase Units 
bw   Body weight 
CAS   Chemical Abstracts Service 
CFU   Colony Forming Units 
CPA   Cyclopiazonic acid 
DNA   Deoxyribonucleic acid 
EC   European Commission and Enzyme Commission 
EFSA   European Food Safety Authority 
EINECS  European Inventory of Existing Commercial Chemical Substances 
EMH   Extramedullary haemopoiesis 
EU   European Union 
FAO   Food and Agricultural Organisation 
FAU   Fungal Alpha-amylase Units 
FXU(S)  Fungal Xylanase Units 
G   Gram 
GLP   Good Laboratory Practice 
GMM   Genetically Modified Microorganisms 
GMO   Genetically Modified Organisms 
GMP   Good Manufacturing Practice 
HUT   Hemoglobin Units Tyrosine  
IUBMB  International Union of Biochemistry and Molecular Biology 
JECFA   Joint FAO/WHO Expert Committee on Food Additives 
KA   Kojic Acid 
kCal   kilo calories 
kDa   kilo Dalton 
kg   Kilogram 
KLU   Kilo Lipase Units 
L   Liter 
LC-MS/MS  Liquid Chromatography/tandem Mass Spectrometry 
MCV   Mean Cell Volume 
mg    Milligram 
ml   Millilitre 
MOE   Margin of exposure 
MS   Mass Spectrometry 
NOAEL  No Observed Adverse Effect Level 
NPA   β-Nitropropionic acid 
OECD   Organisation for Economic Cooperation and Development 
PAHBAH  p-Hydroxy benzoic acid hydrazide  
PCR   Polymerase Chain Reaction 
PHA   Phytohaemagglutinin 
QPS   Qualified Presumption of Safety 
RBC   Red Blood Cell 
SDS-PAGE  Sodium Dodecyl Sulphate-Poly Acrylamide Gel Electrophoresis 
TMDI   Theoretical Maximum Daily Intake 
TOS   Total Organic Solids 
UV   Ultraviolet 
WBC   White Blood Cell  
WHO   World Health Organisation 
